Back to Browse Journals » Blood and Lymphatic Cancer: Targets and Therapy

Blood and Lymphatic Cancer: Targets and Therapy


Journal Articles:

- 54 records -

Uptake of lymphoma-derived exosomes by peripheral blood leukocytes

Ferguson Bennit HR, Gonda A, Oppegard LJ, Chi DP, Khan S, Wall NR

Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:9-23

Published Date: 28 February 2017

Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose

Waclaw J, Sacha T, Stoklosa T

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:101-108

Published Date: 9 September 2015

Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment

Pujals A, Favre L, Gaulard P, Wiels J

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:93-100

Published Date: 29 July 2015

MYC as therapeutic target in leukemia and lymphoma

Cortiguera MG, Batlle-LΓ³pez A, Albajar M, Delgado MD, LeΓ³n J

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:75-91

Published Date: 22 July 2015

The expanding role of bendamustine in chronic lymphocytic leukemia

Nair KS, Ujjani C

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:65-74

Published Date: 8 July 2015

IL-15 as a potential target in leukemia

Xiong Y, Bensoussan D, Decot V

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:55-63

Published Date: 9 April 2015

Targeting CD20 in chronic lymphocytic leukemia

Nahas MR, Arnason JE

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:43-53

Published Date: 10 March 2015

Emerging role of SOX11 in mantle cell lymphoma

Kuci V, NordstrΓΆm L, Jerkeman M, Ek S

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:35-42

Published Date: 27 February 2015

MicroRNAs as B-cell lymphoma biomarkers

Manterola L, Fernandez-Mercado M, Larrea E, Goicoechea I, Arestin M, Armesto M, Hernandez L, Lawrie CH

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:25-34

Published Date: 4 February 2015

Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma

Yoshimitsu M, Arima N

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:17-23

Published Date: 18 December 2014

Preserving fertility in young patients with lymphoma: an overview

Patel B, Rossi BV

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:1-15

Published Date: 18 December 2014

Multiple myeloma: optimal management and long-term disease control

Sriskandarajah P, Davies FE

Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:121-134

Published Date: 6 November 2014

B-cell malignancies: capture-sequencing strategies for identification of gene rearrangements and translocations into immunoglobulin gene loci

Boyle EM, Walker BA, Wardell CP, Leleu X, Davies FE, Morgan GJ

Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:107-119

Published Date: 30 October 2014

Coexistence of primary myelofibrosis and chronic lymphocytic leukemia

Burgstaller S, Thaler J

Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:101-105

Published Date: 3 October 2014

Optimal management of endemic Burkitt lymphoma: a holistic approach mindful of limited resources

Moormann AM, Skiles JL, Otieno JA, Buckle GC, Vik TA

Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:91-99

Published Date: 23 September 2014

Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase

Farina F, Stasia A, Gambacorti-Passerini C

Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:69-79

Published Date: 21 August 2014

Spotlight on nilotinib in the treatment of chronic myelogenous leukemia

Harnicar S, Mathew S

Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:61-67

Published Date: 21 August 2014

Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma

McKinney MS, Beaven AW

Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:45-59

Published Date: 16 August 2014

Splenic marginal zone lymphoma: a review of the clinical presentation, pathology, molecular biology, and management

Teixeira Mendes LS, Du MQ, Matutes E, Wotherspoon A

Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:29-38

Published Date: 17 July 2014

Profile of elotuzumab and its potential in the treatment of multiple myeloma

Liu YC, Szmania S, van Rhee F

Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:15-27

Published Date: 3 June 2014

Emerging targets in human lymphoma: targeting the MYD88 mutation

Wang JQ, Jeelall YS, Horikawa K

Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:53-61

Published Date: 13 August 2013

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma

Gupta VA, Nooka AK, Lonial S, Boise LH

Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:41-51

Published Date: 16 May 2013

MicroRNA dysregulation in B-cell non-Hodgkin lymphoma

Lim EL, Marra MA

Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:25-40

Published Date: 8 May 2013

Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies

Gopalakrishnan S, Tan D

Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:19-24

Published Date: 18 April 2013

Ruxolitinib as an emerging treatment in myelofibrosis

Emanuel RM, Geyer HL, Mesa RA

Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:11-18

Published Date: 9 March 2013

Novel conditioning regimens for bone marrow transplantation

Shi M, Li M, Ikehara S

Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:1-9

Published Date: 8 January 2013

Therapeutic developments in acute lymphoblastic leukemia

MacKenzie A, Kasner M

Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:145-158

Published Date: 27 November 2012

Recent developments in myelofibrosis

Tibes R, Bogenberger JM, Mesa RA

Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:125-136

Published Date: 2 July 2012

Peripheral T cell lymphoma: clinical utility of romidepsin

Zain J, Sawey K

Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:109-115

Published Date: 13 June 2012

Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future

Sinha R, Nastoupil LJ, Flowers CR

Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:87-98

Published Date: 19 April 2012

Advances in the diagnosis and management of lymphoma

Word ZH, Matasar MJ

Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:29-55

Published Date: 3 February 2012

The evaluation and optimal use of rituximab in lymphoid malignancies

Robak T, Robak P, Smolewski P

Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:1-16

Published Date: 4 January 2012

Reduced intensity treatment in early-stage Hodgkin’s lymphoma

Prodduturi P, Armitage JO

Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:23-31

Published Date: 25 November 2011

mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report

Ibeas P, Cantos B, Provencio M.

Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:19-22

Published Date: 8 November 2011

Leptomeningeal myelomatosis in previously treated high-risk kappa light chain multiple myeloma: case report and literature review

Ohanian M, Alaly J, Samuel S, Cable C, Halka K

Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:9-18

Published Date: 28 September 2011

Mantle cell leukemia as a cause of leukostasis

Smith D, Cable C, Chisholm C, Linz W, Koss W, Dobin S, Rappaport E

Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:5-8

Published Date: 28 April 2011

A new era in blood and lymphatic cancer biology and therapy

David Dingli

Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:1-3

Published Date: 8 March 2011